FineMark National Bank & Trust cut its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 7.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 196,586 shares of the biopharmaceutical company's stock after selling 15,412 shares during the period. FineMark National Bank & Trust's holdings in Pfizer were worth $5,215,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer during the 4th quarter valued at $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the fourth quarter valued at about $28,000. Noble Wealth Management PBC purchased a new position in Pfizer in the fourth quarter valued at about $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer in the fourth quarter worth about $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Pfizer
In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is owned by company insiders.
Analyst Ratings Changes
A number of analysts have recently weighed in on the stock. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. Bank of America reissued a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.
Check Out Our Latest Stock Report on Pfizer
Pfizer Stock Performance
PFE traded up $0.19 during trading on Friday, reaching $25.20. 32,322,049 shares of the company's stock were exchanged, compared to its average volume of 39,037,478. The company's fifty day simple moving average is $26.06 and its 200-day simple moving average is $26.94. The stock has a market capitalization of $142.93 billion, a P/E ratio of 17.87, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.
Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.10 earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
